Mesalamine (Canasa) vs Mesalamine (Lialda)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: Aminosalicylate · full Ulcerative Colitis pipeline
Mesalamine (Canasa)
Marketed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Mesalamine (Lialda)
Marketed by Takeda Pharmaceutical Company and partners
NCT00151892 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 829 participants and an objective endoscopic primary endpoint. Lialda was non-inferior to Asacol for six-month endoscopic remission: 83.7% versus 81.5%, with the 95% confidence interval for the difference (-4% to 8%) remaining within the prespecified -10% margin.
Reported efficacy
Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants (met)
Result source: NCT00151892
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Mesalamine (Canasa) | Mesalamine (Lialda) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not posted · NCT00548574 |
| Clinical remission (maintenance) | —Not reported | —Not posted · NCT00548574 |
| Clinical response (induction) | —Not reported | —Not posted · NCT00548574 |
| Endoscopic improvement (induction) | —Not reported | —Not posted · NCT00548574 |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not posted · NCT00548574 |
Clinical remission (induction)
- Mesalamine (Canasa)
- —Not reported
- Mesalamine (Lialda)
- —Not posted · NCT00548574
Clinical remission (maintenance)
- Mesalamine (Canasa)
- —Not reported
- Mesalamine (Lialda)
- —Not posted · NCT00548574
Clinical response (induction)
- Mesalamine (Canasa)
- —Not reported
- Mesalamine (Lialda)
- —Not posted · NCT00548574
Endoscopic improvement (induction)
- Mesalamine (Canasa)
- —Not reported
- Mesalamine (Lialda)
- —Not posted · NCT00548574
Corticosteroid-free remission (maintenance)
- Mesalamine (Canasa)
- —Not reported
- Mesalamine (Lialda)
- —Not posted · NCT00548574
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Mesalamine (Canasa): no structured comparison results are available for Ulcerative Colitis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mesalamine (Canasa)'s landscape · Mesalamine (Lialda)'s landscape